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Edited by Sandro SonninoAbstract Patients suﬀering from Refsum disease have a defect
in the a-oxidation pathway which results in the accumulation of
phytanic acid in plasma and tissues. Our previous studies have
shown that phytanic acid is also a substrate for the x-oxidation
pathway. With the use of speciﬁc inhibitors we now show that
members of the cytochrome P450 (CYP450) family 4 class are
responsible for phytanic acid x-hydroxylation. Incubations with
microsomes containing human recombinant CYP450s (Super-
somesTM) revealed that multiple CYP450 enzymes of the family
4 class are able to x-hydroxylate phytanic acid with the follow-
ing order of eﬃciency: CYP4F3A > CYP4F3B > CYP4F2 >
CYP4A11.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The degradation of the majority of fatty acids occurs via b-
oxidation in mitochondria and peroxisomes. 3-Methyl-
branched-chain fatty acids, however, are not substrates for
regular b-oxidation but ﬁrst need to undergo one round of
a-oxidation in peroxisomes. During a-oxidation a one-carbon
unit is removed from the carboxy-terminus of the fatty acid
yielding the n  1 analogue with the methyl group at position
2. The 2-methyl-branched-chain fatty acid thus formed, can
then undergo normal b-oxidation [1]. The most abundant 3-
methyl-branched chain fatty acid, at least in humans, is phy-
tanic acid (3,7,11,15-tetramethylhexadecanoic acid). Phytol, a
fatty alcohol and a metabolite of chlorophyll, is the precursor
of phytanic acid. Mammals cannot absorb chlorophyll and re-
lease phytol, but are able to convert free phytol into phytanic
acid and to absorb phytanic acid itself. Fats of dairy products
and meat are rich in phytanic acid and phytol since chlorophyll
degradation and the subsequent conversion of phytol to phy-Abbreviations: CYP450, cytochrome P450; ARD, adult Refsum dis-
ease; DDC, diethyldithiocarbamate; 17-ODYA, 17-octadecynoic acid
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doi:10.1016/j.febslet.2006.05.069tanic acid occurs eﬀectively by bacteria present in the rumen
of ruminants.
Phytanic acid accumulates in patients with adult Refsum dis-
ease (ARD, MIM 266500) which is due to a defect in the a-oxi-
dation pathway caused by mutations in one of two genes
including the PAHX gene which codes for phytanoyl-CoA
hydroxylase [2,3], and the PEX7 gene which codes for the
PTS2 receptor [4]. The majority of ARD patients have muta-
tions in the PAHX gene. The increased levels of phytanic acid
in plasma and tissues are thought to be the direct cause for the
pathology of the disease. Among the symptoms are: progres-
sive retinitis pigmentosa, peripheral neuropathy, anosmia, cer-
ebellar ataxia and ichthyosis [5]. The accumulation of phytanic
acid is gradual because phytanic acid originates from dietary
sources. The only known treatment of ARD consists of a diet
low in phytanic acid, which may be combined with plasmaphe-
resis. The diet causes the phytanic acid levels to decrease in pa-
tients and reduces the progression of the disease [5]. This
decrease in phytanic acid rather than its stabilization indicates
that there is another pathway involved in phytanic acid break-
down besides a-oxidation because in many ARD patients the
a-oxidation pathway is completely defective.
There is a third degradation pathway known for fatty acids
besides a- and b-oxidation, namely x-oxidation, which leads to
the formation of a carboxyl group at the x-end of the fatty
acid [6,7]. The ﬁrst step involves hydroxylation of the fatty acid
at the x-end of the molecule. The x-hydroxylated fatty acid is
then converted into the corresponding dicarboxylic acid, which
may either be catalyzed by the subsequent action of an alcohol
dehydrogenase and an aldehyde dehydrogenase, or catalyzed
by a cytochrome P450 (CYP450) enzyme [8]. In the case of
phytanic acid, x-oxidation will introduce a new carboxyl
group on the x-end with a methyl-group at position 2. The
formed x-dicarboxylic acid of phytanic acid, i.e. phytanedioic
acid, can undergo b-oxidation after activation of the x-car-
boxyl group to its CoA-ester in the same manner as 2-
methyl-branched fatty acids.
Earlier studies have provided evidence suggesting that phy-
tanic acid does undergo x-oxidation under in vivo conditions
[9–11]. More recently we have shown that the ﬁrst step of
the x-oxidation pathway, i.e. the x-hydroxylation of phytanic
acid, takes place in rat and human liver microsomes and is cat-
alyzed by one or more members of the CYP450 enzyme super-
family [12,13]. The expression of many of the enzymes which
belong to this family is known to be induced by a large variety
of drugs [14,15]. Hence, induction of the CYP450 responsible
for the x-hydroxylation of phytanic acid may increase the ﬂux
through the x-oxidation pathway, thereby increasing theblished by Elsevier B.V. All rights reserved.
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enzymes have multiple roles in cellular metabolism, the induc-
tion of the CYP450 involved should be as speciﬁc as possible
to reduce unwanted side eﬀects from the administered drugs.
For this reason it is important to identify the speciﬁc
CYP450 involved in the x-hydroxylation of phytanic acid. In
this paper we report our studies on the identiﬁcation of the
CYP450 enzyme(s) involved in the x-hydroxylation of phy-
tanic acid in humans.0 10 20 30 40 50 60
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Fig. 1. Inhibition of x-hydroxyphytanic acid formation in human liver
microsomes by several CYP450 isoform speciﬁc inhibitors. Pooled
human liver microsomes were incubated with phytanic acid in the
presence of the following inhibitors: TMP, trimethoprim (100 lM);
Ket, ketoconazole (1 lM); OP, omeprazole (10 lM); Sulf, sulfaphe-
nozole (10 lM); Q, quinidine (10 lM); F, furafylline (20 lM); TOA,
troleandomycin (100 mM); DDC, diethyldithiocarbamate (100 lM);
17ODYA, 17-octadecynoic acid (1 lM). The bars represent the means
of duplicate experiments.2. Materials and methods
Phytanic acid was obtained from the VU University Medical Center,
Metabolic Laboratory (Dr. H.J. ten Brink, Amsterdam, The Nether-
lands). 3-Hydroxyheptadecanoic acid was from Larodan Fine
Chemicals AB (Malmo¨, Sweden). NADPH and NAD+ were obtained
from Roche (Mannheim, Germany). Methyl-b-cyclodextrin was from
Fluka (Buchs, Switzerland). N,O-bis-(trimethylsilyl)triﬂuoroacetamide
(BSTFA) containing 1% trimethylchlorosilane (TMCS) was from
Pierce (Rockford, IL, USA). Pooled human liver microsomes and hu-
man recombinant CYP450 isoforms (Supersomes) were obtained
from BDGentest (Woburn, MA, USA). The Supersomes used con-
tained also CYP450 reductase and cytochrome b5 in addition to the
CYP450. The CYP450 inhibitors diethyldithiocarbamate (DDC),
furafylline, ketoconazole, 17-octadecynoic acid (17-ODYA), omepra-
zole, quinidine, sulfaphenazole, trimethoprim, and troleandomycin
were purchased from Sigma–Aldrich (St. Louis, MO, USA). All other
chemicals used were of the highest quality possible.
The x-hydroxylation of phytanic acid was measured as described
earlier [12,13] with slight modiﬁcations. In brief, phytanic acid dis-
solved in DMSO was added to a reaction mixture (ﬁnal volume
0.2 ml) containing human liver microsomes (1 mg/ml ﬁnal concentra-
tion), and 100 mM potassium phosphate buﬀer (pH 7.7) containing
methyl-b-cyclodextrin (0.75 mg/ml ﬁnal concentration). When Super-
somes (25 pmol P450/ml) were used in experiments, the protein con-
centration of the reaction mixture was kept constant at 0.75 mg/ml by
adding Insect Control Supersomes. The ﬁnal concentration of phy-
tanic acid was 0.2 mM unless indicated otherwise. Reactions were ini-
tiated by the addition of NADPH (ﬁnal concentration 1 mM) and
terminated after 30 min by adding 0.2 ml of 1 M HCl to the mixture.
Subsequently, 1 ml phosphate-buﬀered saline was added, followed by
100 lL of 12.1 M HCl, and 20 ll of 0.2 mM 3-hydroxyheptadecanoic
acid in DMSO as internal standard. The reaction mixtures were ex-
tracted twice with 4 ml ethylacetate–diethylether (1:1 v/v). Both frac-
tions were collected and the solvents were evaporated under N2. The
extracted fatty acids were derivatized to their corresponding trimethyl-
silyl derivatives for gas chromatography/mass spectrometry analysis as
described previously [12].
During the inhibitor studies the x-hydroxylation assay was per-
formed as described above except that incubations were performed
in the presence of the following inhibitors: trimethoprim (CYP2C8),
sulfaphenazole (CYP2C9), omeprazole (CYP2C19), quinidine
(CYP2D6), DDC (CYP2E1), and ketoconazole (CYP3A4) [16–19].
Furafylline (CYP1A2), DDC (CYP2E1), 17-ODYA (CYP4), and tro-
leandomycin (CYP3A4) were pre-incubated with human liver micro-
somes for 15 minutes as following the protocol of Eagling et al. [16]
in the presence of NADPH before adding phytanic acid to the mixture
and subsequent incubation (30 min). Stock solutions were prepared in
DMSO. Inhibitor concentrations are given in Fig. 1.3. Results
Recently, we showed that phytanic acid is x-hydroxylated in
(pooled) human liver microsomes and that this reaction is cat-
alyzed by one or more CYP450 enzymes [13]. Furthermore, we
found that phytanic acid is not exclusively hydroxylated at the
x-position but also at the (x-1)-position in a 15:1 ratio. In the
present study we have focused only on the formation of x-hydroxyphytanic acid because this compound is formed pre-
dominantly and can be converted into 1,16-phytanedioic acid,
a substrate for subsequent b-oxidation.
To determine which CYP450 contributes to phytanic acid x-
hydroxylation in human liver microsomes, we have incubated
human liver microsomes with a number of CYP450 subfamily
selective inhibitors as described in Section 2. Concentrations
used were derived from previous studies [16–19]. Substantial
inhibition of phytanic acid x-hydroxylation was only found
with ketoconazole, DDC, and 17-ODYA, which are speciﬁc
inhibitors of CYP3A4, CYP2E1 and CYP4 family members,
respectively. Troleandomycin, omeprazole, and trimethoprim
showed minor eﬀects, while with sulfaphenazole, quinidine,
and furafylline no inhibitory eﬀect was observed at all
(Fig. 1). Inspection of the results of Fig. 1 for ketoconazole re-
veals that the formation of x-hydroxyphytanic acid is inhibited
by 30% at a ﬁnal concentration of 1 lM of ketoconazole. This
indicates that ketoconazole is a relatively poor inhibitor of
phytanic acid x-hydroxylation especially since the IC50 value
of ketoconazole for the CYP3A4 enzyme has been established
to be in the nanomolar range [16]. The inhibitory eﬀect of keto-
conazole at higher concentrations as observed in Fig. 1 is prob-
ably due to the fact that at these concentrations ketoconazole
also inhibits other CYP450s, as indeed described in literature
[16,20].
In order to estimate the IC50 values for the inhibitors DDC
and 17-ODYA, we incubated human liver microsomes in the
presence of phytanic acid and diﬀerent concentrations of inhib-
itor (Fig. 2). From the data of Fig. 2A, an IC50 value of DDC
of 90 lM can be calculated (Fig. 2A). Although DDC is often
used as a selective inhibitor of CYP2E1 in the literature
[21,22], DDC is actually a more potent inhibitor of CYP2A6
and CYP2B6 catalyzed reactions (IC50  125 lM for CYP2E1
vs. IC50 6 10 lM for CYP2A6 and CYP2B6 [21]). It can be
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Fig. 3. x-Hydroxyphytanic acid formation by human recombinant
CYP450 isoforms. Microsomes containing individually expressed
human CYP450 isoforms prepared from baculovirus-infected insect
cells (Supersomes) were incubated with phytanic acid in order to
determine their phytanic acid x-hydroxylation capacity. The data
represent the means of duplicate experiments.
Table 1
Kinetic parameters for the formation of x-hydroxyphytanic acid by
CYP4A11, CYP4F2, CYP4F3A and CYP4F3B
Km (lM) Vmax (pmol/min/pmol P450) Vmax/Km
CYP4A11 191 3.7 0.02
CYP4F2 56 3.2 0.06
CYP4F3A 55 48.1 0.87
CYP4F3B 119 26.1 0.22
Km and Vmax values were estimated by non-linear regression analysis of
the data points presented in Fig. 4 in which each data point is the
means of three separate experiments. A single-component Michaelis–
Menten model was used for calculation.
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Fig. 2. Inhibition of the formation of x-hydroxyphytanic acid by
diﬀerent concentrations of DDC (A) and 17-ODYA (B). The inhib-
itory eﬀect of DDC (A) and 17-ODYA (B) on the formation of
x-hydroxyphytanic acid in pooled human liver microsomes is shown.
The data represent the means of duplicate experiments.
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CYP2A6 and 2B6 to the x-hydroxylation of phytanic acid is
only minor, whereas it cannot be excluded that CYP2E1 pos-
sesses phytanic acid x-hydroxylation activity. However, since
DDC is known to inhibit multiple CYP450 isoforms when
used in high concentrations [16,21] it may well be that multiple
CYP450s are involved in the inhibitory action of DDC in addi-
tion to CYP2E1. As shown in Fig. 2B, 17-ODYA was found to
be a potent inhibitor of phytanic acid x-hydroxylation with an
IC50 < 400 nM. 17-ODYA is a fatty acid analogue which acts
through suicide inhibition and is selective for the CYP4 family
of x-hydroxylases (IC 50 < 100 nM [23]) which are involved in
the x-hydroxylation of long-chain fatty acids, arachidonic acid
and leukotrienes [6,7,23–26].
The results described in the previous paragraph indicate that
one or more members of the CYP4 family most likely are in-
volved in the x-hydroxylation of phytanic acid because the
IC50 value found for 17-ODYA is comparable with previouslyreported values for this family of CYP450 enzymes. In order
to substantiate this conclusion, we studied phytanic acid
x-hydroxylation in microsomes containing individually ex-
pressed CYP4s prepared from baculovirus-infected insect cells
(Supersomes). We tested all commercially available members
of the human CYP4 family. Furthermore, we also performed
incubations with Supersomes containing CYP3A4 and
CYP2E1 to verify the conclusion drawn above that the inhibi-
tion observed with ketoconazole and DDC was indeed due to
the non-speciﬁcity of these inhibitors at higher concentrations
(see previous paragraph). Indeed, as shown in Fig. 3, micro-
somes expressing CYP3A4 and CYP2E1 were completely de-
void of phytanic acid x-hydroxylation activity. Among the
CYP4s tested, there were four CYP450s displaying phytanic
acid x-hydroxylation activity: CYP4F3A, CYP4F3B,
CYP4A11 and CYP4F2 (Fig. 3). In order to determine the ki-
netic parameters of the diﬀerent CYP4s we varied the substrate
concentration in the incubation mixture with the four active
CYP4s (Fig. 4). Kinetic parameters were determined by non-
linear regression analysis using a single-component Michae-
lis–Menten model and are depicted in Table 1. The results ob-
tained show that CYP4F3A has the highest catalytic eﬃciency
of the CYP4s tested as concluded from the Vmax/Km ratios (see
Table 1).
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Fig. 4. x-Hydroxyphytanic acid formation as a function of the
amount of substrate in the assay. Supersomes were incubated in
the presence of diﬀerent concentrations of phytanic acid and NADPH
under conditions described in the Methods section. The ratio methyl-b-
cyclodextrin/phytanic acid was kept constant. Lines represent rates
predicted using Michaelis–Menten kinetic parameters derived from
non-linear regression analysis of the results. The data points represent
average values of three experiments. (CYP4F3A (s), CYP4F3B (r),
CYP4F2 (m), CYP4A11 (j)).
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The results described in this paper indicate that among the
CYP4 family members tested in this study, CYP4F3A is the
most eﬃcient enzyme in x-hydroxylating phytanic acid fol-
lowed by CYP4F3B (Table 1). CYP4F3B is a splice variant
of the CYP4F3 gene in liver and diﬀers in only one exon from
CYP4F3A [27]. This has been shown to cause a diﬀerence in
substrate speciﬁcity with CYP4F3A having the highest aﬃnity
for leukotriene B4 (LTB4) and CYP4F3B for arachidonic acid
[28]. In this paper the diﬀerence in substrate speciﬁcity between
the two splice variants is shown by using phytanic acid as a
substrate.
The CYP4F3A enzyme is expressed in polymorphonuclear
leukocytes and was found to be involved in LTB4 x-hydroxyl-
ation, a process required for the degradation of this inﬂamma-
tory agent [29]. Since CYP4F3A is not expressed in liver, this
enzyme cannot be responsible for the phytanic acid x-hydrox-
ylation activity observed in human liver microsomes [28,30].
Based on the results described in this paper other liver CYP4
enzymes able to x-hydroxylate phytanic acid in addition to
CYP4F3B are CYP4A11 and CYP4F2 [31,32]. Although
CYP4A11 shows little phytanic acid x-hydroxylation activity
as compared to CYP4F3A and CYP4F3B, CYP4A family
members are known to be induced by hypolipidemic drugs
and peroxisome proliferators (PP) via PPARa [33], and can
therefore be considered as potential targets for further research
aimed to induce the activity of the a-oxidation pathway of
phytanic acid in ARD patients. Preliminary experiments in
which phytanic acid x-hydroxylation capacity was measured
in liver homogenates of mice fed a diet containing WY14643
(0.1%) have shown that phytanic acid x-hydroxylation is in-
duced approximately 8-fold as compared with normal fed
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